H Inaba1,2, D Pei3, J Wolf2,4, S C Howard1,2, R T Hayden5, M Go1, O Varechtchouk1, T Hahn1, J Buaboonnam1, M L Metzger1,2, J E Rubnitz1,2, R C Ribeiro1,2, J T Sandlund1,2, S Jeha1,2, C Cheng3, W E Evans6,7, M V Relling6,7, C-H Pui1,2. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis,Tennessee, USA. 2. Department of Pediatrics, The University of Tennessee Health Science Center, Memphis,Tennessee, USA. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 4. Department of Infectious Diseases,, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 5. Department of Pathology, St. Jude Children's Research Hospital, USA. 6. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis,Tennessee, USA. 7. Department of Clinical Pharmacy, The University of Tennessee Health Science Center, Memphis, USA.
Abstract
Background: Comprehensive studies on neutropenia and infection-related complications in patients with acute lymphoblastic leukemia (ALL) are lacking. Patients and methods: We evaluated infection-related complications that were grade ≥3 on National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0) and their risk factors in 409 children with newly diagnosed ALL throughout the treatment period. Results: Of the 2420 infection episodes, febrile neutropenia and clinically or microbiologically documented infection were seen in 1107 and 1313 episodes, respectively. Among documented infection episodes, upper respiratory tract was the most common site (n = 389), followed by ear (n = 151), bloodstream (n = 147), and gastrointestinal tract (n = 145) infections. These episodes were more common during intensified therapy phases such as remission induction and reinduction, but respiratory and ear infections, presumably viral in origin, also occurred during continuation phases. The 3-year cumulative incidence of infection-related death was low (1.0±0.9%, n = 4), including 2 from Bacillus cereus bacteremia. There was no fungal infection-related mortality. Age 1-9.9 years at diagnosis was associated with febrile neutropenia (P = 0.002) during induction and febrile neutropenia and documented infection (both P < 0.001) during later continuation. White race was associated with documented infection (P = 0.034) during induction. Compared with low-risk patients, standard- and high-risk patients received more intensive therapy during early continuation and had higher incidences of febrile neutropenia (P < 0.001) and documented infections (P = 0.043). Furthermore, poor neutrophil surge after dexamethasone pulses during continuation, which can reflect the poor bone marrow reserve, was associated with infections (P < 0.001). Conclusions: The incidence of infection-related death was low. However, young age, white race, intensive chemotherapy, and lack of neutrophil surge after dexamethasone treatment were associated with infection-related complications. Close monitoring for prompt administration of antibiotics and modification of chemotherapy should be considered in these patients.
Background: Comprehensive studies on neutropenia and infection-related complications in patients with acute lymphoblastic leukemia (ALL) are lacking. Patients and methods: We evaluated infection-related complications that were grade ≥3 on National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0) and their risk factors in 409 children with newly diagnosed ALL throughout the treatment period. Results: Of the 2420 infection episodes, febrile neutropenia and clinically or microbiologically documented infection were seen in 1107 and 1313 episodes, respectively. Among documented infection episodes, upper respiratory tract was the most common site (n = 389), followed by ear (n = 151), bloodstream (n = 147), and gastrointestinal tract (n = 145) infections. These episodes were more common during intensified therapy phases such as remission induction and reinduction, but respiratory and ear infections, presumably viral in origin, also occurred during continuation phases. The 3-year cumulative incidence of infection-related death was low (1.0±0.9%, n = 4), including 2 from Bacillus cereusbacteremia. There was no fungal infection-related mortality. Age 1-9.9 years at diagnosis was associated with febrile neutropenia (P = 0.002) during induction and febrile neutropenia and documented infection (both P < 0.001) during later continuation. White race was associated with documented infection (P = 0.034) during induction. Compared with low-risk patients, standard- and high-risk patients received more intensive therapy during early continuation and had higher incidences of febrile neutropenia (P < 0.001) and documented infections (P = 0.043). Furthermore, poor neutrophil surge after dexamethasone pulses during continuation, which can reflect the poor bone marrow reserve, was associated with infections (P < 0.001). Conclusions: The incidence of infection-related death was low. However, young age, white race, intensive chemotherapy, and lack of neutrophil surge after dexamethasone treatment were associated with infection-related complications. Close monitoring for prompt administration of antibiotics and modification of chemotherapy should be considered in these patients.
Authors: Matthew M Hsieh; John F Tisdale; Griffin P Rodgers; Neal S Young; Edward L Trimble; Richard F Little Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: A H Gaur; C C Patrick; J A McCullers; P M Flynn; T A Pearson; B I Razzouk; S J Thompson; J L Shenep Journal: Clin Infect Dis Date: 2001-04-20 Impact factor: 9.079
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: Esther M Te Poele; Eveline S J M de Bont; H Marike Boezen; Tom Revesz; Jos P M Bökkerink; Auke Beishuizen; Ilse J M Nijhuis; Claudi S M Oude Nijhuis; Anjo J P Veerman; Willem A Kamps Journal: Eur J Cancer Date: 2007-08-15 Impact factor: 9.162
Authors: Emily R Finch; Laura J Janke; Colton A Smith; Seth E Karol; Deqing Pei; Cheng Cheng; Sue C Kaste; Hiroto Inaba; Ching-Hon Pui; Joshua Wolf; Mary V Relling Journal: Pediatr Blood Cancer Date: 2019-02-13 Impact factor: 3.167
Authors: Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller Journal: Leuk Lymphoma Date: 2020-12-01
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19
Authors: Rosângela Aparecida Mendes Silva; Regina Maria Holanda de Mendonça; Simone Dos Santos Aguiar; Júlia Cervellini Yajima; Fernando Augusto Lima Marson; Silvia Regina Brandalise; Carlos Emílio Levy Journal: Support Care Cancer Date: 2021-08-07 Impact factor: 3.603